<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803203</url>
  </required_header>
  <id_info>
    <org_study_id>16-033</org_study_id>
    <nct_id>NCT02803203</nct_id>
  </id_info>
  <brief_title>Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers</brief_title>
  <official_title>A Phase 1/2 Study of Combination Osimertinib and Bevacizumab as Treatment for Patients With EGFR-mutant Lung Cancers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the safety of combining the drugs osimertinib and&#xD;
      bevacizumab at different dose levels. The investigators want to find out what effects, good&#xD;
      and/or bad, taking osimertinib and bevacizumab has on the patient and lung cancer. This study&#xD;
      will try to find the best dose of osimertinib and bevacizumab given together that does not&#xD;
      cause significant side effects. Once the investigators determine that combining osimertinib&#xD;
      and bevacizumab is safe, they want to see if the combination is effective in treating lung&#xD;
      cancers with the EGFR mutation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2016</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose (MTD) (Phase I)</measure>
    <time_frame>1 year</time_frame>
    <description>The MTD (maximum tolerated dose)/recommended phase 2 dose will be the highest dose level at which &lt;1 DLT is detected in the first cycle for 6 treated patients. If only 3 patients are treated at a dose level being considered for the MTD, an additional 3 patients will be enrolled.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression-free survival (Phase II)</measure>
    <time_frame>12 months</time_frame>
    <description>Tumor response will be assessed using RECIST 1.1. A CT chest/abdomen/pelvis will be performed to demonstrate all known areas of measurable disease.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>EGFR-mutant Lung Cancers</condition>
  <arm_group>
    <arm_group_label>osimertinib and bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 1:&#xD;
3+3 dose escalation design 2 dose levels Dose level -1: Osimertinib 40mg daily Maximum accrual = 12 Bevacizumab 15mg/kg q3 weeks Dose level 1: Osimertinib 80mg daily Bevacizumab 15mg/kg q3 Weeks&#xD;
Phase 2:&#xD;
Use MTD determined during phase 1</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>osimertinib</intervention_name>
    <arm_group_label>osimertinib and bevacizumab</arm_group_label>
    <other_name>AZD9291</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <arm_group_label>osimertinib and bevacizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Advanced biopsy-proven metastatic non-small cell lung cancer&#xD;
&#xD;
          -  Somatic activating mutation in EGFR&#xD;
&#xD;
          -  No prior treatment with an EGFR TKI&#xD;
&#xD;
          -  No prior treatment with a VEGF inhibitor&#xD;
&#xD;
          -  Measurable (RECIST 1.1) indicator lesion not previously irradiated&#xD;
&#xD;
          -  Karnofsky performance status (KPS) ≥ 70%&#xD;
&#xD;
          -  Age &gt;18 years old&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
               -  AST, ALT ≤ 3 x ULN&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5x ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5x ULN OR calculated creatinine clearance &gt; 60ml/min&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1000 cells/mm3&#xD;
&#xD;
               -  Hemoglobin≥8.0 g/dL&#xD;
&#xD;
               -  Platelets ≥100,000/mm3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any contra-indications to bevacizumab which include but are not limited to recent&#xD;
&#xD;
               1. Any previous venous thromboembolism &gt; NCI CTCAE Grade 3&#xD;
&#xD;
               2. Severe uncontrolled hypertension (systolic blood pressure ≥150 mmHg and/or&#xD;
                  diastolic blood pressure ≥ 100mmHg)&#xD;
&#xD;
               3. Cardiovascular disease including stroke of myocardial infarction &lt;6 months prior&#xD;
                  to study enrollment, New York Heart Association Grade 2 or greater congestive&#xD;
                  heart failure, serious cardiac arrythmia uncontrolled by medication&#xD;
&#xD;
               4. Hemorrhagic brain metastases. Asymptomatic (not requiring escalating doses of&#xD;
                  steroids) brain metastases are acceptable.&#xD;
&#xD;
               5. History of severe proteinuria (urine dipstick ≥ 2+ or 24 hr urine &gt; 2gm/24hr)&#xD;
&#xD;
               6. Prior history of hypertensive crisis or hypertensive encephalopathy&#xD;
&#xD;
               7. History of a central nervous system disease (e.g. seizures) unrelated to cancer&#xD;
                  unless adequately treated with standard medical therapy&#xD;
&#xD;
               8. Significant vascular disease (e.g. aortic aneurysm requiring surgical repair)≥ 6&#xD;
                  months prior to study enrollment&#xD;
&#xD;
               9. History of hemoptysis (≥1/2 teaspoon of bright red blood per episode) within the&#xD;
                  last 3 months&#xD;
&#xD;
              10. Evidence of a bleeding diathesis or significant coagulopathy (in the absence of&#xD;
                  therapeutic anticoagulation)&#xD;
&#xD;
              11. Current or recent (within 10 days of study drug start) use of aspirin (&gt;325mg&#xD;
                  daily), clopidogrel (&gt;75mg daily).&#xD;
&#xD;
              12. Recent initiation of full dose oral or parental anticoagulants that have not been&#xD;
                  in place for at least 2 weeks.&#xD;
&#xD;
              13. Tumor invading or abutting major blood vessels&#xD;
&#xD;
              14. Tumor histology classified by squamous cell histology.&#xD;
&#xD;
              15. Any history of abdominal fistula or GI perforation within 6 months of study&#xD;
                  enrollment&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Any type of systemic anticancer therapy (chemotherapy or experimental drugs) within 2&#xD;
             weeks of starting treatment on protocol&#xD;
&#xD;
          -  Any radiotherapy within 1 week of starting treatment on protocol&#xD;
&#xD;
          -  Any major surgery within 4 weeks of starting treatment on protocol&#xD;
&#xD;
          -  Any evidence of clinically significant interstitial lung disease&#xD;
&#xD;
          -  Known hypersensitivity to any component of bevacizumab and osimertinib&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helena Yu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering commack</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mskcc.org/</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>June 14, 2016</study_first_submitted>
  <study_first_submitted_qc>June 14, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <last_update_submitted>December 17, 2020</last_update_submitted>
  <last_update_submitted_qc>December 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osimertinib</keyword>
  <keyword>bevacizumab</keyword>
  <keyword>metastatic</keyword>
  <keyword>16-033</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

